Alcon and RxSight team up to develop light-adjustable cataract lenses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazil’s Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Oil settles lower on peace hopes, Saudi attacks limit losses
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
RxSight Inc. (RXST) PT Lowered to $6.50 at BofA Securities
July 7, 2026 12:24 PM EDTBofA Securities analyst Craig Bijou lowered the price target on RxSight Inc. (NASDAQ: RXST) to $6.50 (from $8.00) while maintaining a Underperform rating.
The analyst comments "RXST pre-Ad preliminary Q2 sales of $27m vs Street of $32m and lowered 2026 guidance by $13m at... More



